How Plaques Actually Form

The Autophagic-Lysosomal Origin of Alzheimer’s Disease: A Comprehensive Analysis of the PANTHOS Mechanism and the "Inside-Out" Plaque Hypothesis

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

1. Executive Summary

The prevailing conceptual framework for Alzheimer’s disease (AD) research for the past three decades has been the Amyloid Cascade Hypothesis, which posits that the extracellular accumulation of \beta-amyloid (A$\beta$) into senile plaques is the primary pathogenic event driving neurodegeneration. However, the persistent failure of amyloid-clearing therapeutics to arrest cognitive decline has necessitated a rigorous re-evaluation of this paradigm. This report presents an exhaustive analysis of the alternative "Inside-Out" hypothesis, spearheaded by the research of Ralph Nixon and colleagues, which identifies the failure of the neuronal autophagic-lysosomal pathway (ALP) as the true etiological origin of AD. Based on a detailed examination of the progressive timelines and ultrastructural data presented in Nixon’s work, specifically the "time course of AD" charts, this report establishes that the disease mechanism begins decades before plaque formation. The pathology initiates with a molecular defect in lysosomal acidification, driven by the inhibition of the vacuolar H+-ATPase (v-ATPase) complex by the \beta-carboxy-terminal fragment of the amyloid precursor protein (APP-\betaCTF). This acidification failure leads to a "traffic jam" of autophagy, resulting in the massive accumulation of undigested, A$\beta$-laden autophagic vacuoles. This intracellular crisis culminates in the formation of PANTHOS (poisonous anthos/flower) neurons—a distinct, pre-death cellular state characterized by perikaryal rosettes of autophagic vacuoles and membrane blebbing. The eventual lysis of these PANTHOS neurons releases their intracellular amyloid burden into the extracellular space, creating the dense-core senile plaque. Thus, the plaque is not an external precipitate but the "tombstone" of a neuron that died from lysosomal failure. This report details the molecular mechanisms, temporal progression, and downstream consequences of this pathway, providing a nuanced understanding of AD as a genetically driven lysosomal storage disorder.

2. Introduction: The Historical Context and the Need for a Paradigm Shift

2.1 The Stagnation of the Amyloid Cascade

Since the isolation of the \beta-amyloid peptide in 1984, the field of Alzheimer’s research has been dominated by the view that extracellular plaques are the causative agents of toxicity. This "Amyloid Cascade Hypothesis" suggested a linear sequence: extracellular A$\beta$ deposition leads to tau hyperphosphorylation, which leads to neuroinflammation, synaptic loss, and cell death. Consequently, the vast majority of therapeutic development focused on monoclonal antibodies designed to clear these extracellular deposits. However, clinical reality has contradicted this model. While agents such as aducanumab and lecanemab successfully reduce plaque burden, their impact on cognitive decline is marginal at best, and they do not halt the disease. Furthermore, neuropathological studies have long noted a "anatomical disconnect" where the location of amyloid plaques does not correlate well with the regions of profound neuron loss or cognitive, symptoms. These discrepancies suggest that the plaque is a late-stage marker—a consequence rather than a cause—of a deeper, earlier dysfunction.

2.2 The Emergence of the Lysosomal Hypothesis In contrast to the extracellular focus, the work of Ralph Nixon’s laboratory at the Center for Dementia Research has elucidated a pathway of destruction that occurs entirely within the neuron. This "Inside-Out" model proposes that AD is fundamentally a disease of waste clearance. Neurons, being post-mitotic cells that must function for a lifetime, are uniquely dependent on the autophagy-lysosome pathway to remove damaged organelles and protein aggregates. The Nixon model, supported by extensive ultrastructural analysis of human brains and AD mouse models, posits that this clearance system fails very early in the disease process—during the "preclinical" phase shown in progression charts. This failure is not a secondary effect of amyloid but the primary driver of amyloidosis. The "chart" referenced in this analysis serves as a temporal map of this failure, tracing the trajectory from molecular acidification defects to the macroscopic devastation of the brain. 3. Physiology of the Neuronal Autophagy-Lysosome

Pathway (ALP)

To understand the pathology of AD as described in the Nixon charts, one must first establish the baseline physiology of the neuronal ALP. The neuron faces unique challenges compared to other cell types due to its extreme polarization (axons and dendrites) and its inability to dilute waste through cell division. 3.1 The Autophagic Process: Induction to Clearance Macroautophagy (hereafter referred to as autophagy) is a multi-step catabolic process: 1. Induction and Sequestration: In response to stress or nutrient deprivation, a double-membrane structure called the phagophore forms. It elongates and sequesters cytoplasmic cargo (e.g., mitochondria, protein aggregates) to form the autophagosome. 2. Transport: In neurons, autophagosomes are primarily formed in distal axons and synapses. They must be transported retrogradely along microtubules to the cell body (soma), where lysosomes are concentrated. 3. Maturation: During transport, autophagosomes fuse with late endosomes to form amphisomes, acquiring necessary machinery for lysosomal fusion. 4. Fusion and Digestion: The autophagosome fuses with a lysosome to form an autolysosome. 5. Degradation: The acidic environment of the lysosome (pH 4.5–5.0) activates hydrolases (e.g., cathepsins, glucocerebrosidase) which degrade the inner membrane and the cargo. 6. Recycling: The resulting amino acids, lipids, and nucleotides are exported back into the cytoplasm for reuse. 3.2 The Critical Role of Lysosomal Acidification The entire efficacy of this pathway hinges on the maintenance of a highly acidic luminal pH within the lysosome. This acidity is non-negotiable for two reasons: 1. Enzyme Activation: Most lysosomal hydrolases, particularly the cathepsins (B, D, L), are synthesized as inactive zymogens that structurally rearrange into active enzymes only at low pH. 2. Membrane Trafficking: The acidic pH is required for the proper sorting of vesicles and the fusion events between autophagosomes and lysosomes.

This acidification is generated and maintained by the vacuolar H+-ATPase (v-ATPase), a

massive protein complex that functions as a rotary proton pump. 3.2.1 The v-ATPase Complex The v-ATPase consists of two domains:

● V1 Sector: A cytosolic subcomplex responsible for ATP hydrolysis. It contains the

catalytic subunits. ● V0 Sector: A membrane-embedded subcomplex that forms the proton pore.

● Mechanism: ATP hydrolysis in V1 drives the rotation of the central stalk, which forces

protons through the V0 channel into the lysosomal lumen. The assembly and disassembly of V1 and V0 are regulated to control pH; dissociated sectors are inactive. In the context of the Nixon chart and AD pathology, the integrity of this pump is the single most critical variable. As we will detail, the disruption of this specific complex is the "Patient Zero" event of Alzheimer’s Disease. 4. The Molecular Etiology: The Acidification Defect The Nixon progression chart begins with a decline in lysosomal function. The underlying mechanism for this decline has been identified as a specific molecular interaction between a metabolite of the Amyloid Precursor Protein (APP) and the v-ATPase complex. 4.1 The Role of APP-\betaCTF (C99) While the Aβ peptide receives the most attention, it is merely a cleavage product of a larger precursor. APP is first cleaved by \beta-secretase (BACE1) to generate the

\beta-carboxy-terminal fragment (APP-\betaCTF), also known as C99. This fragment remains

embedded in the membrane until it is further cleaved by \gamma-secretase to release Aβ. In AD, and particularly in Down Syndrome (where APP is triplicated), APP-\betaCTF accumulates in the endosomal-lysosomal system. Nixon’s research has proven that APP-\betaCTF is not an innocent bystander but a potent inhibitor of the lysosome. 4.1.1 The Inhibitory Mechanism The mechanism of inhibition is precise and structural:

1. Phosphorylation: The YENPTY motif on the cytosolic tail of APP-\betaCTF is

phosphorylated at Tyrosine-682 (Tyr682). This phosphorylation is mediated by Fyn

kinase, which is notably overactive in AD brains. 2. Binding: The phosphorylated APP-\betaCTF binds directly to the V0a1 subunit of the v-ATPase complex. 3. Disassembly: This binding occupies the site required for the V1 sector to attach to the V0 sector. Consequently, the pump cannot assemble. The V1 motor is decoupled from the V0 pore, and proton transport ceases. 4.2 PSEN1 Mutations and Calcium Dysregulation While APP-\betaCTF provides a direct mechanism for acidification failure in sporadic AD and Down Syndrome, mutations in PSEN1 (Presenilin-1) drive a parallel pathway to the same result in Familial AD. Presenilin-1 acts as a chaperone for the v-ATPase V0a1 subunit, aiding its N-glycosylation and stability. Loss of PSEN1 function leads to a deficit of functional v-ATPase. Furthermore, PSEN1 regulates the lysosomal calcium channels TRPML1 and TPC2.

● The Calcium Connection: In PSEN1-mutant neurons, lysosomal calcium homeostasis is

disrupted. This leads to a calcium efflux that activates cytosolic calpain proteases. Calpains are destructive enzymes that degrade the neuronal cytoskeleton and further impair vesicle trafficking.

● Synergy: Whether through APP-\betaCTF inhibition (in sporadic/DS cases) or PSEN1

dysfunction (in familial cases), the convergence point is lysosomal de-acidification. 4.3 Table 1: Mechanisms of Lysosomal Failure in AD Subtypes AD Subtype Primary Defect Mechanism of Result v-ATPase Inhibition

Sporadic AD / Late Accumulation of Phospho-APP-\betaCT Rising Lysosomal pH

Onset APP-\betaCTF F binds V0a1 subunit, blocking V1 assembly.

Down Syndrome 3 copies of APP gene Overproduction of Rising Lysosomal pH

(Trisomy 21) APP-\betaCTF leads to

massive v-ATPase inhibition.

Familial AD (PSEN1) PSEN1 Mutation Defective Rising Lysosomal pH

N-glycosylation of V0a1; TRPML1/Ca2+ dysregulation. 5. Analyzing the Chart: The Temporal Progression of

Pathology

The "Time Course of AD" chart presented in Nixon’s papers is not merely a sequence of symptoms but a biological timeline of the "Inside-Out" mechanism. We can parse this timeline into distinct phases, integrating the research snippets to explain the unseen cellular reality of each stage. 5.1 Phase I: The Preclinical "Intraneuronal" Stage

● Chart visualization: This phase corresponds to the earliest time points, decades before

dementia. The curves for "Lysosomal Acidification" and "Proteolytic Turnover" begin to plummet.

● Biological Activity

○ The Traffic Jam Begins: As v-ATPase activity declines (due to the mechanisms

described in Section 4), the pH of lysosomes rises from 4.8 to 5.5 and higher. At these pH levels, cathepsins lose efficiency.

○ Induction-Clearance Mismatch: Paradoxically, the neuron senses this metabolic

stress and increases autophagy induction. This is a maladaptive response. The neuron generates more autophagosomes to clean up the mess, but because the lysosomes (the garbage trucks) are broken, this only adds to the congestion.

○ Formation of pa-AL: The result is the accumulation of poorly acidified autolysosomes (pa-AL). These are hybrid organelles that have fused but cannot

degrade their contents. They begin to fill the cell body. 5.2 Phase II: The Accumulation Phase (Intracellular Amyloidosis)

● Chart visualization: The curve for "Intraneuronal Aβ" rises sharply. The curve for

"Autophagic Vacuoles" peaks.

● Biological Activity

○ The Bioreactor Effect: The pa-ALs are not just passive storage containers; they

become incubators for amyloid. BACE1 and \gamma-secretase are present in these vesicles and remain active at slightly elevated pH levels where degradative enzymes fail.

○ Intraluminal Aggregation: Within the pa-AL, APP-\betaCTF is cleaved into

Aβ. Because the cathepsins that would normally degrade Aβ (like Cathepsin B) are inactive, the concentration of Aβ rises exponentially inside the vesicle. This leads to the formation of Aβ oligomers and fibrils within the membrane-bound compartments of the cell.

○ Nucleation: The acidic-but-not-acidic-enough environment of the pa-AL provides

the perfect chemical conditions for Aβ nucleation, catalyzing the formation of the dense core that will eventually characterize the plaque. 5.3 Phase III: The PANTHOS Transformation

● Chart visualization: The timeline shows the emergence of "PANTHOS neuron death"

overlapping with the appearance of "Amyloid Plaques."

● Biological Activity

○ This is the critical transition point described in the 2022 Nature Neuroscience paper. The burden of pa-ALs becomes so massive that the neuron undergoes a radical structural change, discussed in detail in Section 6. The neuron is now a "ticking time bomb." 5.4 Phase IV: The Extracellular Phase (Clinical AD)

● Chart visualization: The curves for "Extracellular Plaques," "Tau Tangles," and

"Cognition" (decline) rise steeply after the peak of intraneuronal pathology.

● Biological Activity

○ The Explosion: The PANTHOS neurons undergo lysis. The intracellular amyloid

core is released.

○ The Aftermath: Microglia swarm the debris (the plaque). The loss of the neuron

and the inflammatory response drive the clinical symptoms of dementia. 6. The PANTHOS Phenomenon: Ultrastructural

Analysis

The term PANTHOS (Poisonous Anthos/Flower) was coined by Lee and Nixon to describe the

unique, flower-like morphology of neurons in the terminal stage of autophagy failure. This is not a subtle change; it is a gross deformation of the neuronal soma visible under specific staining conditions. 6.1 Structural Components of PANTHOS Using the tfLC3 (tandem fluorescent LC3) probe and electron microscopy, the Nixon lab identified the specific features of PANTHOS: 1. The "Petals" (Perikaryal Rosettes): ○ The cytoplasm is packed with giant, Aβ-positive autophagic vacuoles. These vacuoles cluster together and press against the plasma membrane, causing it to bulge outward in distinct "blebs." ○ These blebs radiate from the center of the cell, resembling the petals of a flower.

○ Composition: These vesicles are LC3-positive (indicating autophagy origin) but

lack acidity (indicating lysosomal failure). They contain undigested mitochondria and massive amounts of Aβ. 2. The "Core" (Nuclear Compression): ○ The nucleus is often intact but condensed and displaced by the expanding network of vacuoles.

○ Perinuclear Tubules: Surrounding the nucleus is a dense network of membrane

tubules. These are believed to be the result of autophagosomes fusing with the endoplasmic reticulum (ER). Within these tubules, Aβ fibrils can be seen accumulating intraluminally. 3. The "Thorns" (Aβ Fibrils): ○ Crucially, the amyloid in PANTHOS neurons is not amorphous; it is fibrillar. The high concentration within the pa-ALs drives the Aβ to form the cross-beta sheet structure characteristic of plaques while still inside the living cell. 6.2 The Stages of PANTHOS The research identifies a progression even within the PANTHOS state: ● Stage i (Early): Loss of acidification in autolysosomes (pH shift). ● Stage ii (Flowering): Focal plasma membrane bulging as pa-ALs enlarge and proliferate. The "rosette" pattern begins to form.

● Stage iii (Full PANTHOS): The entire soma is transformed into a mass of vacuoles and

blebs. The nucleus is degenerating. This is the terminal state before lysis. 6.3 Table 2: Characteristics of PANTHOS Neurons vs. Healthy Neurons Feature Healthy Neuron PANTHOS Neuron

Lysosomal pH Acidic (< 5.0) Elevated (> 6.0)

Autophagic Vacuoles Rare (rapid clearance) Abundant / Packed (clearance

failure)

Amyloid Location Minimal / Secreted Intracellular (within pa-ALs and

tubules)

Morphology Smooth soma Membrane blebs / Flower-like

rosettes

Marker Profile Cathepsin D active Cathepsin D inactive but

abundant; LC3 positive 7. The "Inside-Out" Hypothesis: Mechanisms of

Plaque Formation

The identification of PANTHOS provides the structural basis for the "Inside-Out" Amyloid

Plaque Hypothesis. This hypothesis resolves the longstanding debate regarding the origin of

senile plaques, shifting the model from extracellular precipitation to intracellular necrosis. 7.1 The Sequence of Plaque Genesis The transition from a PANTHOS neuron to a senile plaque is a deterministic physical process: 1. Intracellular Incubation: As described, the PANTHOS neuron acts as a containment vessel. It holds a dense core of fibrillar Aβ within its membrane-bound vacuolar network. This core is geometrically identical to the center of a dense-core plaque. 2. Lysosomal Membrane Permeabilization (LMP): The membranes of the pa-ALs, stretched to their limit and subjected to oxidative stress from the undigested cargo, eventually rupture. 3. The Death Event: The rupture of lysosomes releases cathepsins into the cytoplasm. Although the cytosolic pH is neutral (limiting cathepsin activity), the massive release of enzymes and stored calcium triggers necrosis. The plasma membrane disintegrates. 4. Release ("Inside-Out"): The contents of the neuron—the "flower"—are spilled into the extracellular space. The membranous debris is rapidly degraded by glial cells, but the protease-resistant amyloid core remains. 5. The Plaque "Tombstone": What remains is a dense core of amyloid, surrounded by a halo of dystrophic neurites (the disconnected axons of the dead cell) and glial cells. The location of the plaque marks the exact coordinates of the neuron that died. 7.2 Evidence for the Model This sequence is supported by quantitative analysis in AD mouse models (5xFAD, Tg2576):

● Co-localization: Using 3D confocal imaging, researchers showed that individual

PANTHOS neurons map 1:1 to new senile plaques. The volume of the intracellular amyloid mass matches the volume of the resulting plaque core.

● Sourcing: The plaques retain markers of their intracellular origin, such as lysosomal

proteins (LAMP1, Cathepsin D) which are found embedded within the amyloid matrix of the plaque. This "lysosomal signature" serves as a forensic fingerprint of the plaque's origin. 8. Downstream Cascades: Tau, Inflammation, and

Neurodegeneration

The Nixon model posits that lysosomal failure is the upstream driver of the other major hallmarks of AD: neurofibrillary tangles (Tau) and neuroinflammation. 8.1 The Lysosome-Tau Connection For years, Amyloid and Tau were viewed as separate pathologies. The lysosomal hypothesis unifies them. Autophagy is the primary mechanism for clearing soluble, hyperphosphorylated Tau (p-Tau). When autophagy fails (the "traffic jam"), p-Tau accumulates. Furthermore, the calcium dysregulation associated with lysosomal failure (via PSEN1/TRPML1 defects) plays a causative role in Tau pathology:

● Calpain Activation: The efflux of calcium from dysfunctional lysosomes activates

calpains.

● CDK5 Activation: Calcium/calpain signaling activates CDK5 (Cyclin-dependent kinase

5). ● Hyperphosphorylation: Activated CDK5 and other kinases hyperphosphorylate Tau, causing it to detach from microtubules and aggregate into Neurofibrillary Tangles (NFTs).

● Proteolytic Cleavage: Calpains can also cleave Tau into toxic fragments that seed

further aggregation.

● Conclusion: Tau tangles are a direct metabolic consequence of the same lysosomal

failure that creates plaques. 8.2 Microglia and the Inflammatory Response Microglia are the brain's immune sentinels. In the context of PANTHOS, their role is reactive.

● Surveillance: Microglia likely detect the distress signals (ATP, danger-associated

molecular patterns) emitted by the stressed PANTHOS neuron before it dies.

● Containment: Upon neuronal lysis, microglia migrate to the site of the new plaque. Their

primary function is to contain the damage. They extend processes to surround the amyloid core, attempting to compact it and prevent the spread of toxic oligomers.

● Failure: However, in AD, microglia often become "exhausted" or dysfunctional

themselves. They may fail to degrade the amyloid (which is resistant to proteolysis) and instead release pro-inflammatory cytokines (IL-1β, TNFα), which damage surrounding healthy neurons, potentially triggering autophagy failure in neighbors—propagating the disease. 9. Comparative Neuropathology: AD as a Lysosomal

Storage Disorder

One of the most profound insights from the Nixon group is the reclassification of Alzheimer’s Disease. The pathology described—massive accumulation of undigested autophagic vacuoles, specific enzyme deficiencies, and lysosomal acidification defects—is phenotypically identical to a family of genetic diseases known as Lysosomal Storage Disorders (LSDs). 9.1 AD and Niemann-Pick Type C (NPC) Nixon draws a direct parallel between AD and Niemann-Pick Type C (NPC), a childhood neurodegenerative disorder caused by mutations in cholesterol transport proteins (NPC1/2).

● Similarities: Both diseases exhibit

○ Enlarged endosomes (early endosome anomalies are a hallmark of both). ○ Accumulation of APP-\betaCTF. ○ Profound autophagic vacuole accumulation. ○ Formation of Neurofibrillary Tangles (NPC is one of the few non-AD diseases with NFTs).

● The Link: The fact that a "pure" lysosomal genetic defect (NPC) causes AD-like

pathology (tangles and plaques) strongly reinforces the argument that lysosomal failure is the cause of AD pathology, not a side effect. 9.2 The "Drift" Hypothesis This comparison supports a "threshold" or "drift" model of AD. ● In Familial AD, a genetic mutation (PSEN1, APP) breaks the lysosome early in life, leading to early-onset dementia.

● In Sporadic AD, the natural aging process leads to a gradual decline in lysosomal

acidification and v-ATPase efficiency. When this decline crosses a critical threshold—perhaps exacerbated by lifestyle, vascular health, or minor genetic risk factors (APOE4)—the PANTHOS cascade is triggered. This explains why age is the primary risk factor for sporadic AD: it takes decades for the lysosome to "rust" to the point of failure. 10. Clinical and Therapeutic Implications The "Inside-Out" / PANTHOS model offers a rigorous explanation for the failures of past clinical trials and a roadmap for future success. 10.1 Why Antibody Therapies Fail Drugs like aducanumab, lecanemab, and donanemab are designed to strip amyloid plaques from the brain. They are remarkably effective at doing this. However, they barely impact the clinical trajectory of the disease.

● Explanation: According to the Nixon model, the plaque is the tombstone of a neuron that

is already dead. Removing the tombstone does not bring the neuron back. Furthermore, these drugs do not address the underlying lysosomal acidification defect in the living neurons (the PANTHOS neurons) that are currently degenerating. The disease process (autophagy failure) continues unabated, regardless of whether the extracellular debris is cleared. 10.2 Future Therapeutic Targets The Nixon "chart" and the PANTHOS mechanism point toward entirely new classes of

therapeutics focused on lysosomal rejuvenation

1. Re-acidification Agents: Therapies that can restore lysosomal pH. This could involve:

○ v-ATPase Agonists: Drugs that stabilize the V1-V0 assembly or prevent

APP-\betaCTF binding. ○ Acidifying Nanoparticles: Delivery of acidic polymers to the lysosome. ○ cAMP/PKA Modulation: Signaling pathways that upregulate v-ATPase activity. 2. APP-\betaCTF Reduction: ○ Targeting BACE1 (\beta-secretase) to prevent the formation of the C99 fragment. While BACE inhibitors have failed in the past (likely due to timing or side effects), the Nixon model suggests they might be effective if used specifically to rescue lysosomal pH in early stages.

○ Fyn Kinase Inhibitors: Blocking the phosphorylation of APP at Tyr682 to prevent

its interaction with v-ATPase. 3. TRPML1 Agonists: ○ Drugs that activate the TRPML1 channel to correct calcium dysregulation and promote lysosomal exocytosis (clearing the waste). 4. Autophagy Modulation (The "Goldilocks" Problem): * While boosting autophagy is often proposed, the Nixon model suggests caution. In AD, induction is already high; the problem is clearance. Boosting induction without fixing the lysosome (the "sink") might actually accelerate PANTHOS formation by generating more waste that cannot be degraded. Therapy must focus on the clearance side of the equation. 11. Conclusion The comprehensive analysis of Ralph Nixon’s research, particularly the progression charts and the PANTHOS discovery, compels a restructuring of our understanding of Alzheimer’s Disease. The data demonstrates that AD is not a disease of extracellular toxicity, but a catastrophic failure of the neuron’s internal waste management system. The trajectory is clear: molecular inhibition of the v-ATPase by APP metabolites leads to lysosomal de-acidification. This triggers a massive, decades-long accumulation of autophagic waste (PANTHOS) that ultimately kills the neuron from the inside out. The senile plaque—long the target of billion-dollar drug campaigns—is merely the debris field left behind by this cellular explosion. By shifting the focus from the plaque to the lysosome, and from extracellular amyloid to intracellular acidification, the Nixon model provides not only a better explanation for the available data but also a hopeful new direction for therapeutic intervention. The cure for Alzheimer’s will likely not be found in sweeping away the ashes of the dead neurons, but in relighting the acidic fire within the living ones.

Citations

Works cited

1. Nixon Lab Provides Further Evidence for Alternative Alzheimer's Theory,

https://www.nki.rfmh.org/nixon-lab-provides-further-evidence-for-alternative-alzheimers-theory/

2. Evidence Mounts for Alternate Origins of Alzheimer's Disease Plaques | NYU Langone News, https://nyulangone.org/news/evidence-mounts-alternate-origins-alzheimers-disease-plaques

3. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases - Center for Dementia Research, https://www.cdr.rfmh.org/wp-content/uploads/2025/02/Nixon-2024-Nature-Review-MCB.pdf

4. Nixon RA. Autophagy-lysosomal-associated neuronal death in neurodegenerative disease. Acta Neuropathol 2024;148(1):42. DOI 10.1007/s00401-024-02799-7.

5. Autophagy–lysosomal pathway (ALP) abnormalities progress during an... - ResearchGate, https://www.researchgate.net/figure/Autophagy-lysosomal-pathway-ALP-abnormalities-progress -during-an-exceptionally-early_fig2_383949656

6. Lysosomal dysfunction in Down Syndrome and Alzheimer mouse models is caused by selective v-ATPase inhibition by Tyr682 phosphorylated APP βCTF | bioRxiv, DOI 10.1101/2022.06.02.494546">https://www.biorxiv.org/content/10.1101/2022.06.02.494546

7. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease--locating the primary defect. Neurobiol Dis 2011;43(1):38-45. DOI 10.1016/j.nbd.2011.01.021.

8. Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, Pensalfini A, et al.. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci 2022;25(6):688-701. DOI 10.1038/s41593-022-01084-8.

9. The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer's Disease? - MDPI, https://www.mdpi.com/2073-4409/12/3/454

10. Reviving 'inside-out' hypothesis of amyloid beta to explain Alzheimer's mysteries, https://www.thetransmitter.org/alzheimers-disease/reviving-inside-out-hypothesis-of-amyloid-bet a-to-explain-alzheimers-mysteries/

11. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol 2024;25(11):926-946. DOI 10.1038/s41580-024-00757-5.

12. Autophagy, amyloidogenesis and Alzheimer disease - Company of Biologists journals, https://journals.biologists.com/jcs/article/120/23/4081/35101/Autophagy-amyloidogenesis-and-Al zheimer-disease

13. Lysosomal dysfunction in Down Syndrome and Alzheimer mouse models is caused by selective v-ATPase inhibition by Tyr phosphorylat - bioRxiv, DOI 10.1101/2022.06.02.494546">https://www.biorxiv.org/content/10.1101/2022.06.02.494546

14. V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities - MDPI, https://www.mdpi.com/2073-4409/13/17/1441

15. Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, et al.. Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol Psychiatry 2016;21(5):707-16. DOI 10.1038/mp.2015.97.

16. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) | Journal of Neuroscience, https://www.jneurosci.org/content/39/27/5255

17. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 2013;37(12):1949-61. DOI 10.1111/ejn.12169.

18. Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res Rev 2016;32:75-88. DOI 10.1016/j.arr.2016.05.004.

19. TfLC3 probe reveals a unique pattern of autophagic stress, AL pH... - ResearchGate, https://www.researchgate.net/figure/TfLC3-probe-reveals-a-unique-pattern-of-autophagic-stressAL-pH-deficit-and-plasma_fig4_361040251

20. Opening the box of PANTHORA in Alzheimer's disease - ResearchGate, https://www.researchgate.net/publication/364116497_Opening_the_box_of_PANTHORA_in_Alz

heimer's_disease

21. Nixon RA. Autophagy-lysosomal-associated neuronal death in neurodegenerative disease. Acta Neuropathol 2024;148(1):42. DOI 10.1007/s00401-024-02799-7.

22. Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J 2017;31(7):2729-2743. DOI 10.1096/fj.201700359.

23. Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance, https://www.researchgate.net/publication/5434392_Dynamics_of_the_MicroglialAmyloid_Interac tion_Indicate_a_Role_in_Plaque_Maintenance

24. Henningfield CM, Soni N, Lee RW, Sharma R, Cleland JL, Green KN. Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer's disease mouse model. Alzheimers Res Ther 2024;16(1):101. DOI 10.1186/s13195-024-01470-3.

25. Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain - eScholarship, https://escholarship.org/uc/item/5j31m56f

26. Colacurcio DJ, Pensalfini A, Jiang Y, Nixon RA. Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. Free Radic Biol Med 2018;114:40-51. DOI 10.1016/j.freeradbiomed.2017.10.001.

27. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol 2024;25(11):926-946. DOI 10.1038/s41580-024-00757-5.

28. Lo CH, Zeng J. Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. Transl Neurodegener 2023;12(1):29. DOI 10.1186/s40035-023-00362-0.

29. Too Basic: APP β-CTF's YENTPY Motif Binds Proton Pump, Thwarts Lysosomes - Alzforum, https://www.alzforum.org/news/research-news/too-basic-app-v-ctfs-yentpy-motif-binds-proton-pu mp-thwarts-lysosomes

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.